Advertisement

JBIC Journal of Biological Inorganic Chemistry

, Volume 23, Issue 6, pp 949–956 | Cite as

Anti-prostate cancer activity of 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazide copper complexes in vivo by bioluminescence imaging

  • Fang Xie
  • Huawei Cai
  • Fangyu Peng
Original Paper
  • 211 Downloads

Abstract

Copper 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazide complex (CuHQTS) is a copper complex with strong anticancer activity against cisplatin-resistant neuroblastoma and prostate cancer cells in vitro by cell proliferation assay or fluorescent microscopic imaging. This study aimed to evaluate anti-prostate cancer activity of CuHQTS in vivo by bioluminescence imaging (BLI) and tumor size measurement, using athymic nu/nu mice implanted with prostate cancer cells carrying luciferase reporter gene (Luc-PC3). Growth of Luc-PC3 cells (1 × 105 cells) implanted in athymic nu/nu mice treated with CuHQTS for 2 weeks was suppressed by measurement of luciferase signals (6.18 × 107 to 5.36 × 107 p/s/cm2/sr) with BLI, compared with luciferase signals of Luc-PC3 cells (4.66 × 107 to 1.51 × 108 p/s/cm2/sr, p < 0.05) in the mice treated with normal saline of placebo control. Moreover, the size of PC-3 xenograft tumor (126.5 ± 34.2 mm3) in athymic nu/nu mice treated with CuHQTS was significantly smaller than the size of PC-3 xenograft tumor (218.6 ± 48.0 mm3, p < 0.05) in athymic nu/nu mice treated with normal saline of placebo control, suggesting in vivo tumor growth inhibition activity of CuHQTS on prostate cancer. The findings of this study support further investigation of CuHQTS as a promising new anticancer agent for the treatment of metastatic prostate cancer refractory to anticancer drugs currently available.

Keywords

Prostate cancer Anticancer copper complex CuHQTS Bioluminescence Imaging 

Notes

Acknowledgements

The authors thank Haiyuan Zhang for synthesis of CuHQTS used for this study. This study was supported by a faculty research development fund awarded to F. P by Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center for financial support. The study was also supported in part with infrastructure of the Southwestern Small Animal Imaging Resource provided by 1P30 CA142543 and P41-EB015908.

References

  1. 1.
    Berger MF, Lawrence MS, Demichelis F et al (2011) Nature 470:214–220CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A (2017) CA Cancer J Clin 67:7–30CrossRefPubMedGoogle Scholar
  3. 3.
    Muhammad N, Guo Z (2014) Curr Opin Chem Biol 19:144–153CrossRefPubMedGoogle Scholar
  4. 4.
    Florea AM, Busselberg D (2011) Cancers 3:1351–1371CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Dasari S, Tchounwou PB (2014) Eur J Pharmacol 740:364–378CrossRefPubMedGoogle Scholar
  6. 6.
    Siddik ZH (2003) Oncogene 22:7265–7279CrossRefPubMedGoogle Scholar
  7. 7.
    Tabti R, Tounsi N, Gaiddon C, Bentouhami E, Desaubry L (2017) Med Chem 7:875–879CrossRefGoogle Scholar
  8. 8.
    Chaudhary A, Singh A (2016) Int J Curr Res Chem Pharm Sci 3:57–67CrossRefGoogle Scholar
  9. 9.
    Santini C, Pellei M, Gandin V, Porchia M, Tisato F, Marzano C (2014) Chem Rev 114:815–862CrossRefPubMedGoogle Scholar
  10. 10.
    French FA, Freedlander BL (1958) Cancer Res 18:1290PubMedGoogle Scholar
  11. 11.
    Petering HG, Buskirk HH, Underwood GE (1964) Cancer Res 24:367PubMedGoogle Scholar
  12. 12.
    Zhang H, Wu JS, Peng F (2008) Anticancer Drugs 19:125–132CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang H, Thomas R, Oupicky D, Peng F (2008) J Biol Inorg Chem 13:47–55CrossRefPubMedGoogle Scholar
  14. 14.
    Cater MA, Pearson HB, Wolyniec K et al (2013) ACS Chem Biol 8:1621–1631CrossRefPubMedGoogle Scholar
  15. 15.
    Palanimuthu D, Shinde SV, Somasundaram K, Samuelson AG (2013) J Med Chem 56:722–734CrossRefPubMedGoogle Scholar
  16. 16.
    Xie F, Peng F (2017) J Fluoresc 27:1937–1941CrossRefPubMedGoogle Scholar
  17. 17.
    Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, Antich PP, Mason RP (2004) Mol Imaging 3:117–124CrossRefPubMedGoogle Scholar
  18. 18.
    Tisato F, Marzano C, Porchia M, Pellei M, Santini C (2010) Med Res Rev 30:708–749PubMedGoogle Scholar
  19. 19.
    Luker GD, Luker KE (2008) J Nucl Med 49:1–4CrossRefPubMedGoogle Scholar
  20. 20.
    Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH (1999) Neoplasia 1:303–310CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Contag CH, Jenkins D, Contag PR, Negrin RS (2000) Neoplasia 2:41–52CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kaijzel EL, van der Pluijm G, Lowik CW (2007) Clin Cancer Res 13:3490–3497CrossRefPubMedGoogle Scholar
  23. 23.
    Licha K, Olbrich C (2005) Adv Drug Deliv Rev 57:1087–1108CrossRefPubMedGoogle Scholar
  24. 24.
    Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS (2008) Nat Rev Drug Discov 7:591–607CrossRefPubMedGoogle Scholar
  25. 25.
    Rudin M, Weissleder R (2003) Nat Rev Drug Discov 2:123–131CrossRefPubMedGoogle Scholar
  26. 26.
    Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD (2001) Laryngoscope 111:696–701CrossRefPubMedGoogle Scholar
  27. 27.
    Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD (2003) Clin Cancer Res 9:1666–1672PubMedGoogle Scholar
  28. 28.
    Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK (2000) Clin Cancer Res 6:1–10PubMedGoogle Scholar
  29. 29.
    Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN (2007) Mol Cancer Ther 6:1039–1045CrossRefPubMedGoogle Scholar
  30. 30.
    Pan Q, Kleer CG, Van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD (2002) Cancer Res 62:4854–4859PubMedGoogle Scholar
  31. 31.
    Mihich E, Simpson CL, Mulhern AI (1965) Cancer Res 25:1417–1431PubMedGoogle Scholar
  32. 32.
    Yuan J, You Y, Lu X, Muzik O, Oupicky D, Peng F (2007) Mol Imaging 6:10–17CrossRefPubMedGoogle Scholar
  33. 33.
    Yuan J, Zhang H, Kaur H, Oupicky D, Peng F (2013) Mol Imaging 12:203–212CrossRefPubMedGoogle Scholar
  34. 34.
    Hrkach J, Hoff DV, Ali MM et al (2012) Sci Trans Med 4:128–139CrossRefGoogle Scholar
  35. 35.
    Cai H, Xie F, Mulgaonkar A, Chen L, Sun X, Hsieh JT, Peng F, Tian R, Li L, Wu C, Ai H (2018) Nanomedicine.  https://doi.org/10.2217/nnm-2018-0062 CrossRefPubMedGoogle Scholar
  36. 36.
    Kularatne SA, Wang K, Santhapuram HK, Low PS (2009) Mol Pharm 6:780–789CrossRefPubMedGoogle Scholar
  37. 37.
    Tykvart J, Schimer J, Bařinková J et al (2014) Bioorg Med Chem 22:4099–4108CrossRefPubMedGoogle Scholar

Copyright information

© SBIC 2018

Authors and Affiliations

  1. 1.Department of RadiologyUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.PET Center, Huashan HospitalFudan UniversityShanghaiChina
  3. 3.Department of Nuclear Medicine, West China HospitalSichuan UniversityChengduChina
  4. 4.Advanced Imaging Research CenterUniversity of Texas Southwestern Medical CenterDallasUSA
  5. 5.Harold C. Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations